Ataxia Telengectasia

Disclaimer: This information is provided for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment and consider individual patient circumstances when making healthcare decisions. Always consult with a qualified healthcare professional for any medical concerns or before making any decisions related to patient care.

Overview

• Definition: Ataxia Telangiectasia (A-T) is a rare, autosomal recessive, progressive neurodegenerative disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, variable immunodeficiency, increased susceptibility to certain cancers (especially lymphoid malignancies), and extreme sensitivity to ionizing radiation. It results from mutations in the ATM (ataxia telangiectasia mutated) gene.
• Epidemiology:
  • Prevalence: Estimated to be between 1 in 40,000 to 1 in 100,000 live births worldwide, though specific prevalence rates vary by population.
  • Carrier Frequency: Approximately 1-2% of the general population are heterozygous carriers.
  • Sex: Affects males and females equally.
  • Onset: Typically manifests in early childhood, often between 1-4 years of age.
• Classification: A-T is primarily classified by its genetic basis (mutations in ATM). There are no distinct clinical subtypes, but variability in the severity and age of onset of symptoms exists, which can sometimes be correlated with the specific type of ATM mutation (e.g., null mutations vs. hypomorphic mutations). "Classic" A-T refers to the full clinical spectrum with early onset and rapid progression, while "variant" or "mild" A-T may refer to cases with later onset and slower progression, sometimes associated with residual ATM protein function.

Pathophysiology

• Mechanism: A-T is caused by homozygous or compound heterozygous mutations in the ATM gene located on chromosome 11q22-23. The ATM gene encodes a serine/threonine protein kinase (ATM protein), which is a key component of the cellular response to DNA double-strand breaks (DSBs).
  • DNA Repair Defect: The ATM protein is activated by DSBs and orchestrates a complex signaling cascade that includes cell cycle checkpoint activation, DNA repair, and apoptosis. In A-T, defective ATM protein leads to impaired recognition and repair of DSBs, resulting in genomic instability.
  • Cellular Consequences:
    • Cerebellar Degeneration: Purkinje cells are particularly vulnerable to accumulated DNA damage, leading to their progressive loss and cerebellar atrophy, manifesting as ataxia.
    • Immunodeficiency: Impaired V(D)J recombination in lymphocytes (a process involving DSBs), crucial for immunoglobulin and T-cell receptor diversity, contributes to immunodeficiency.
    • Cancer Predisposition: Unrepaired DNA damage and genomic instability increase the risk of chromosomal translocations and mutations, predisposing to cancer, particularly lymphoid malignancies.
    • Radiation Sensitivity: Cells from A-T patients are hypersensitive to ionizing radiation (which induces DSBs) due to their inability to properly repair radiation-induced DNA damage, leading to increased cell death and chromosomal aberrations.
• Risk Factors:
  • Genetic Predisposition: Having two copies of a mutated ATM gene (autosomal recessive inheritance). Both parents must be carriers of an ATM mutation, usually without showing symptoms themselves.
• Protective Factors: None identified for preventing the development of A-T, as it is a genetic disorder. Management focuses on preventing or mitigating complications.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Progressive Cerebellar Ataxia: Usually the first symptom, appearing in infancy or early childhood (1-4 years). Initially presents as truncal ataxia, dyspraxia of gait, followed by limb ataxia, dysarthria, and oculomotor apraxia. Progression leads to wheelchair dependence, typically by adolescence.
  • Oculocutaneous Telangiectasias: Dilated blood vessels, typically appearing on the bulbar conjunctiva (corners of eyes) between 3-6 years of age, then on sun-exposed areas of the skin (e.g., ears, neck, antecubital and popliteal fossae).
  • Immunodeficiency: Variable, affecting both humoral and cellular immunity. Predisposes to recurrent sinopulmonary infections (e.g., sinusitis, otitis media, pneumonia). Common deficiencies include IgA, IgG2, IgE, and T-cell lymphopenia.
  • Increased Cancer Risk: Significantly elevated lifetime risk for various malignancies, particularly lymphomas (e.g., non-Hodgkin lymphoma), leukemias (e.g., acute lymphoblastic leukemia), and sometimes solid tumors (e.g., breast cancer, gastric carcinoma).
• Early Signs:
  • Gait Instability: Truncal ataxia, frequent falls, unsteady gait, difficulty with balance and coordination. Often initially misdiagnosed as cerebral palsy.
  • Speech Difficulties: Dysarthria (slurred, slow, monotonous speech).
  • Ocular Motor Apraxia: Difficulty initiating voluntary eye movements (saccades) without head thrusts.
• Advanced Signs:
  • Severe Neurological Impairment: Profound ataxia, dystonia, choreoathetosis, muscle weakness, peripheral neuropathy, and cognitive decline (though often mild). Wheelchair dependence is common.
  • Chronic Lung Disease: Bronchiectasis, pulmonary fibrosis due to recurrent infections.
  • Endocrine Abnormalities: Insulin resistance, impaired glucose tolerance, and sometimes diabetes mellitus.
  • Growth Retardation: Short stature.
  • Premature Aging Features: Grey hair, skin atrophy.
• Atypical Presentations:
  • Later Onset A-T: Milder neurological progression, later onset of telangiectasias, or less severe immunodeficiency due to hypomorphic ATM mutations.
  • Non-Classic Features: Predominant dystonia or choreoathetosis early in the disease course, or significant spasticity.

Physical Examination

• Inspection:
  • Gait: Ataxic, wide-based, unsteady.
  • Posture: Truncal instability, titubation.
  • Telangiectasias: Visible dilated blood vessels, particularly on the bulbar conjunctiva (often bilateral and symmetric, beginning at the nasal and temporal limbus), ears, neck, and flexural creases.
  • Speech: Dysarthric, slurred, slow, monotonous.
  • Growth: May reveal short stature, signs of malnutrition.
• Palpation:
  • Muscle Tone: May show hypotonia initially, evolving to dystonia or spasticity in advanced stages.
  • Skin: May reveal signs of chronic infection or dermatological issues.
• Special Tests:
  • Neurological Examination:
    • Cerebellar Signs: Dysmetria (finger-to-nose, heel-to-shin), dysdiadochokinesia, intention tremor.
    • Oculomotor Apraxia: Inability to initiate voluntary horizontal saccades without head thrusts; smooth pursuits may be jerky.
    • Deep Tendon Reflexes: May be diminished or absent due to peripheral neuropathy in later stages.
    • Proprioception/Vibration Sense: May be impaired.
  • Immunological Assessment: Look for signs of chronic or recurrent sinopulmonary infections (e.g., clubbing, reduced breath sounds).

Diagnostic Approach

History Taking

• Key Questions:
  • Developmental Milestones: Age of walking, onset of gait unsteadiness, regression of motor skills.
  • Neurological Progression: How has the ataxia progressed? Are there other movement disorders (dystonia, chorea)? Speech changes? Swallowing difficulties?
  • Recurrent Infections: Frequency, type, and severity of infections (pneumonia, sinusitis, otitis media, skin infections). Need for antibiotics or hospitalizations.
  • Ocular/Skin Changes: Onset and location of red eyes or skin lesions.
  • Family History: Consanguinity? Siblings with similar symptoms? Any family history of ataxia, immunodeficiency, or early-onset cancers?
  • School Performance: Any cognitive or learning difficulties.
  • Nutritional Status: Weight loss, poor feeding, GI symptoms.
• Red Flags:
  • Progressive cerebellar ataxia in a young child.
  • Recurrent, severe, or unusual infections.
  • Unexplained elevated alpha-fetoprotein (AFP).
  • Oculocutaneous telangiectasias in conjunction with ataxia.
  • History of siblings with similar progressive neurological or immunological issues.
  • Unusual sensitivity to radiation (e.g., severe reactions to routine X-rays or radiotherapy).

Laboratory Tests

• First-Line:
  • Alpha-Fetoprotein (AFP): Highly elevated in over 95% of A-T patients by 8-10 months of age, usually reaching levels above 10 ng/mL and often hundreds or thousands of ng/mL. This is a critical screening marker. Levels typically increase with age.
  • Immunoglobulin Levels:
    • IgA: Often deficient (primary IgA deficiency is common, ~50-80%).
    • IgG subclasses: IgG2 and IgG4 deficiency are common.
    • IgE: Often low or absent.
    • IgM: Usually normal or elevated.
  • Lymphocyte Subsets:
    • T-cell lymphopenia: Reduced total T-cells (CD3+), particularly helper T-cells (CD4+).
    • B-cell and NK cell counts: Variable, often normal.
  • Antibody Responses to Vaccines: Impaired specific antibody responses to polysaccharide antigens (e.g., pneumococcal vaccine) even if baseline Ig levels are normal.
• Confirmatory:
  • Genetic Testing:
    • Sequence analysis of the ATM gene: Gold standard for diagnosis, identifying pathogenic mutations in ATM. Full gene sequencing is recommended due to the large size of the gene and wide spectrum of mutations.
    • Deletion/Duplication analysis: To detect larger genomic rearrangements not found by sequencing.
  • Chromosomal Breakage Studies: Increased spontaneous and radiation-induced chromosomal breaks (e.g., using G-banded karyotyping with challenges like bleomycin or ionizing radiation) in cultured lymphocytes or fibroblasts. This is a functional test demonstrating genomic instability, but genetic testing is now preferred for primary diagnosis.
• Monitoring:
  • Routine CBC with differential: To monitor for cytopenias, particularly neutropenia or lymphopenia.
  • Immunoglobulin levels: Periodically, to assess need for IVIG/SCIG.
  • Lung function tests: Spirometry, if age-appropriate, to monitor for chronic lung disease (e.g., bronchiectasis).
  • Glucose monitoring: Oral glucose tolerance test (OGTT) or HbA1c, due to risk of insulin resistance and diabetes.
  • Cancer surveillance: Age-appropriate screening based on risk (e.g., annual clinical exam, imaging for unexplained lymphadenopathy or organomegaly, flow cytometry for suspicious blood counts).
  • Vitamin E levels: Due to reported low levels in some patients, though significance is debated.

Imaging

• Recommended:
  • Brain MRI:
    • Findings: Progressive cerebellar atrophy (especially superior vermis), T2 hyperintensities in the dentate nuclei, and sometimes white matter changes. These findings support the clinical diagnosis but are not specific to A-T. Useful for assessing progression and ruling out other conditions.
• Advanced:
  • Chest CT: High-resolution CT (HRCT) of the chest is recommended for evaluating chronic cough or recurrent infections to detect and monitor bronchiectasis and other chronic lung changes.
  • PET-CT / CT scans: As needed for cancer screening or staging, especially for unexplained lymphadenopathy, hepatosplenomegaly, or other suspicious masses.
  • Swallowing studies (videofluoroscopy): If dysphagia is suspected, to assess aspiration risk.

Management

Management of A-T is primarily supportive and multidisciplinary, aimed at mitigating symptoms, preventing complications, and improving quality of life. There is currently no cure.

Acute Management

• Immediate:
  • Acute Infections: Prompt and aggressive treatment of bacterial infections (e.g., pneumonia, sepsis) with appropriate broad-spectrum antibiotics, adjusted based on culture and sensitivity.
  • Acute Neurological Deterioration: Assess for treatable causes (e.g., infection, hydrocephalus if present, severe metabolic derangement).
• Stabilization:
  • Respiratory Support: Oxygen therapy for hypoxemia, respiratory support (non-invasive or invasive ventilation) for respiratory failure due to severe infections or neuromuscular weakness.
  • Fluid and Electrolyte Management: Address dehydration or electrolyte imbalances, especially during acute illness.
• Emergency:
  • Sepsis/Septic Shock: Rapid administration of IV fluids, vasopressors, and broad-spectrum antibiotics.
  • Acute Lymphoma/Leukemia: Urgent oncology consultation for diagnosis and initiation of chemotherapy; extreme caution with radiation exposure due to severe hypersensitivity.

Chronic Management

• Pharmacological:
  • Immunoglobulin Replacement Therapy (IVIG/SCIG):
    • Indications: Recommended for patients with documented IgG deficiency (IgG levels < 400-500 mg/dL) or recurrent severe bacterial infections despite adequate antibiotic therapy, even with normal IgG levels but impaired specific antibody responses.
    • Dosage: Typically 400-600 mg/kg IVIG every 3-4 weeks, or equivalent SCIG doses. Aim for trough IgG levels > 700 mg/dL.
  • Antibiotics:
    • Prophylactic Antibiotics: For patients with severe recurrent sinopulmonary infections or bronchiectasis (e.g., azithromycin daily/three times weekly, or trimethoprim-sulfamethoxazole daily).
    • Acute Infections: Prompt treatment with culture-guided antibiotics.
  • Corticosteroids: May be considered for severe movement disorders (e.g., dystonia), but long-term use is limited due to side effects.
  • Amantadine/Benzodiazepines/Botulinum Toxin: For managing severe chorea, dystonia, or spasticity. Doses are individualized.
  • Antioxidants: Vitamin E supplementation (e.g., 200-800 IU/day) sometimes used due to oxidative stress theories, but evidence of clinical benefit is limited.
  • Insulin: For managing diabetes mellitus.
• Non-pharmacological:
  • Physical Therapy (PT): Essential to maintain mobility, strength, balance, and prevent contractures. Focus on gait training, coordination exercises, balance activities.
  • Occupational Therapy (OT): To optimize daily living activities, recommend adaptive equipment (e.g., walkers, wheelchairs, weighted utensils), and provide strategies for independence.
  • Speech Therapy (ST): To improve dysarthria, manage dysphagia (swallowing difficulties), and minimize aspiration risk. May involve dietary modifications (e.g., thickened liquids, pureed foods).
  • Nutritional Support: High-calorie, nutrient-dense diet to combat weight loss and growth failure. May require feeding tubes (e.g., gastrostomy tube) if severe dysphagia leads to malnutrition or aspiration.
  • Pulmonary Care: Aggressive chest physiotherapy, postural drainage, nebulized mucolytics (e.g., hypertonic saline) to clear airway secretions and manage bronchiectasis.
  • Psychological Support: For patients and families dealing with a progressive debilitating illness.
  • Genetic Counseling: For affected families and extended relatives for carrier testing.
• Monitoring: Long-term follow-up is lifelong and multidisciplinary.
  • Neurological: Regular assessment of motor function, speech, and swallowing.
  • Immunological: Annual Ig levels, lymphocyte subsets, and assessment of vaccine responses.
  • Pulmonary: Regular clinical assessment, chest X-rays, and HRCT chest as indicated.
  • Oncological Surveillance: Close monitoring for signs of malignancy (e.g., unexplained fever, weight loss, lymphadenopathy, hepatosplenomegaly, abnormal blood counts). No standardized screening protocols, but high index of suspicion is crucial.
  • Endocrine: Annual glucose screening (HbA1c or OGTT).

Treatment Algorithms

• First-Line:
  1. Diagnosis Confirmation: Genetic testing for ATM mutations.
  2. Multidisciplinary Team: Establish care with neurology, immunology, pulmonology, oncology, gastroenterology/nutrition, physical therapy, occupational therapy, and speech therapy.
  3. Symptomatic Management:
     • Ataxia/Movement Disorders: PT/OT, speech therapy. Pharmacological agents for specific movement disorders (e.g., dystonia, chorea) as needed.
     • Immunodeficiency: Prophylactic antibiotics for recurrent infections; IVIG/SCIG for documented significant hypogammaglobulinemia or impaired specific antibody responses.
     • Pulmonary: Chest physiotherapy, aggressive treatment of infections.
     • Nutrition: Dietary management, supplement, or G-tube if required.
• Second-Line:
  • Uncontrolled Movement Disorders: Trials of additional medications or botulinum toxin injections for focal dystonia.
  • Severe Recurrent Infections: Optimize IVIG/SCIG dosing, adjust prophylactic antibiotic regimens, consider specialized pulmonary treatments.
• Refractory Cases:
  • Advanced Neurological Dysfunction: Focus shifts to comfort, palliative care, and management of severe dysphagia and aspiration pneumonia.
  • Refractory Infections/Bronchiectasis: May require more aggressive respiratory interventions, potentially including lung transplant in highly selected cases (very rare due to multisystem nature of disease).
  • Malignancy: Treatment protocols must be modified due to extreme radiation sensitivity. Reduced-intensity chemotherapy regimens are often required. All radiation therapy should be avoided or used with extreme caution and reduced doses if absolutely necessary.

Complications

• Common:
  • Recurrent sinopulmonary infections (pneumonia, sinusitis, otitis media).
  • Bronchiectasis and chronic lung disease.
  • Progressive neurological dysfunction leading to loss of ambulation and severe dysarthria.
  • Malnutrition and failure to thrive due to dysphagia and increased metabolic demands.
• Serious:
  • Lymphoid Malignancies: Non-Hodgkin lymphoma and acute lymphoblastic leukemia are significant causes of mortality.
  • Aspiration Pneumonia: A major cause of morbidity and mortality due to severe dysphagia.
  • Respiratory Failure: Due to chronic lung disease or acute severe infections.
  • Sepsis: From overwhelming infections.
  • Diabetes Mellitus: Due to insulin resistance.
• Long-term:
  • Chronic neurological disability (wheelchair dependence, severe speech impairment).
  • Chronic lung disease requiring ongoing support.
  • Increased risk of other cancers (e.g., gastric adenocarcinoma, breast cancer).
  • Premature aging.
  • Significant impact on quality of life and lifespan.

Prognosis

• Factors:
  • Type of ATM Mutation: Null mutations generally lead to more severe phenotypes and earlier onset/progression. Hypomorphic mutations may result in a milder, later-onset course.
  • Severity of Immunodeficiency: Greater susceptibility to infections correlates with poorer outcomes.
  • Development of Malignancy: Lymphoma and leukemia are major contributors to mortality.
  • Effectiveness of Supportive Care: Proactive management of infections, nutrition, and respiratory issues can significantly impact quality of life and prolong survival.
• Survival:
  • Historically, most patients did not survive beyond adolescence or early adulthood.
  • With improved diagnostic methods and aggressive multidisciplinary supportive care, particularly for infections and nutrition, life expectancy has increased. Many patients now survive into their 20s and 30s, and some into their 40s or beyond, though often with significant disability.
  • Leading causes of death are chronic lung disease, severe infections, and cancer.
• Quality of Life: Significantly impacted by progressive neurological disability (loss of ambulation, severe dysarthria, and sometimes cognitive decline), chronic infections, and cancer. Requires extensive caregiver support and adaptive equipment.

Prevention

• Primary: Not applicable, as A-T is a genetic disorder.
• Secondary:
  • Early Diagnosis: Crucial for initiating supportive care early, preventing complications, and informing families about genetic risks.
  • Genetic Counseling: Essential for affected families. Provides information about autosomal recessive inheritance, risk of recurrence (25% for each subsequent child of carrier parents), and options for prenatal diagnosis (chorionic villus sampling or amniocentesis) or preimplantation genetic diagnosis (PGD) for future pregnancies.
• Tertiary: Focuses on preventing complications and improving quality of life for diagnosed individuals.
  • Infection Prophylaxis: Prophylactic antibiotics, immunoglobulin replacement.
  • Aggressive Management of Infections: Prompt diagnosis and treatment.
  • Pulmonary Hygiene: Regular chest physiotherapy to prevent bronchiectasis and chronic lung disease.
  • Nutritional Support: Prevent malnutrition and aspiration.
  • Regular Surveillance: For early detection of malignancy (though no standardized screening protocol exists, a high index of suspicion is paramount).
  • Radiation Avoidance: Crucial for diagnostic imaging and therapeutic interventions. Standard X-rays should be minimized. CT scans should be used judiciously, and MRI is preferred when possible. Radiotherapy for cancer should be avoided or delivered with extreme caution and reduced doses.
  • Vaccinations: Routine immunizations should be given, though live attenuated vaccines (e.g., MMR, varicella) are generally contraindicated in patients with severe immunodeficiency (consider inactivated alternatives if available and indicated). Responses to vaccines may be suboptimal.

Special Populations

• Pediatric:
  • A-T is primarily a pediatric disease, with symptoms typically appearing in early childhood.
  • Diagnosis often occurs after initial motor developmental delays are noted.
  • Emphasis on early intervention (PT, OT, ST) and prompt management of infections.
  • Care coordination among multiple specialists is critical.
  • Parental education and support are paramount.
• Geriatric:
  • Most A-T patients do not reach geriatric age due to the severe progressive nature of the disease and life-limiting complications.
  • Those with milder "variant" forms may survive longer, potentially experiencing more pronounced features of premature aging, endocrinopathies, and chronic organ dysfunction.
• Pregnancy:
  • Pregnancy in women with A-T is exceedingly rare due to the severe chronic illness, significant disability, and often impaired fertility.
  • If pregnancy were to occur, specific considerations would include medication safety, management of immunodeficiency during pregnancy, and monitoring for increased maternal complications.
• Comorbidities:
  • Diabetes Mellitus: Requires standard diabetes management (diet, insulin).
  • Chronic Lung Disease (Bronchiectasis): Requires ongoing pulmonary hygiene, aggressive treatment of exacerbations, and possibly long-term prophylactic antibiotics.
  • Cancers: Requires highly individualized oncological management, with a strong emphasis on avoiding radiation therapy and considering reduced-intensity chemotherapy protocols due to extreme radiation sensitivity.

Clinical Pearls

• Diagnostic:
  • "Red eyes and wobbly walk": A classic mnemonic for the combination of ataxia and telangiectasias.
  • Elevated AFP: Consider A-T in any child with progressive ataxia and unexplained elevated AFP (after 8-10 months of age). It's a highly sensitive, though not specific, marker.
  • Misdiagnosis Trap: A-T is often initially misdiagnosed as cerebral palsy due to the early onset of motor difficulties.
  • Genetic Test is Key: While clinical features and AFP can strongly suggest A-T, genetic testing for ATM mutations is essential for definitive diagnosis and genetic counseling.
• Treatment:
  • Multidisciplinary Care is Non-negotiable: A-T affects multiple systems, requiring a coordinated team approach.
  • Radiation is Toxic: NEVER use radiation therapy for A-T patients without extreme caution and expert consultation on dose reduction. Minimize diagnostic radiation (X-rays, CTs). MRI is generally safer.
  • Proactive Infection Management: Don't wait for severe infections; consider prophylactic antibiotics and IVIG/SCIG based on immunological status.
  • Nutritional Support is Crucial: Malnutrition exacerbates weakness and susceptibility to infection. Monitor weight and consider G-tube if oral intake is insufficient or aspiration is a concern.
• Pitfalls:
  • Ignoring AFP: Dismissing an elevated AFP in a child with ataxia can delay diagnosis.
  • Assuming "mild" presentation: Even with later onset or less severe initial symptoms, A-T is a progressive disease with significant long-term complications.
  • Standard cancer treatment: Applying standard chemotherapy/radiotherapy protocols for malignancy without adjusting for radiation sensitivity can be fatal.
  • Neglecting genetic counseling: Failing to inform families about genetic risks and reproductive options.

Recent Updates

• Guidelines:
  • The Ataxia-Telangiectasia Clinical Center Network (ATCCN) provides comprehensive clinical management guidelines, regularly updated based on emerging evidence.
  • Ongoing efforts to standardize international clinical care recommendations.
• Evidence:
  • Therapeutic Trials: Research is ongoing into various therapeutic approaches, including:
    • Pharmacological Chaperones: Investigating compounds that might correct protein folding defects in some ATM mutations.
    • Gene Therapy/Gene Editing: Early-stage research exploring the potential for gene correction.
    • Anti-inflammatory/Neuroprotective Agents: Targeting downstream pathways affected by ATM deficiency, such as oxidative stress or chronic inflammation.
    • Repurposed Drugs: E.g., studies on efficacy of N-acetyl cysteine (NAC) as an antioxidant or other compounds for specific symptoms like dystonia.
  • Biomarker Discovery: Continued research into additional biomarkers for disease progression and treatment response.
  • Deep Phenotyping: Better understanding of the wide spectrum of clinical manifestations and their correlation with specific ATM mutations.
• Controversies:
  • Role of Corticosteroids: While sometimes used for severe movement disorders, long-term efficacy and optimal dosing remain debated.
  • Benefit of Antioxidants: Despite theoretical benefits, strong clinical evidence for specific antioxidant supplementation significantly altering disease course is still lacking.
  • Optimal Cancer Surveillance: No consensus on best screening practices for malignancies in A-T patients, balancing risk of radiation exposure with early detection.

Key References

• Guidelines:
  • Ataxia-Telangiectasia Clinical Center Network (ATCCN) Clinical Management Guidelines: Often published in specialized journals or available on ATCCN/A-T Children's Project websites.
  • European Society for Immunodeficiencies (ESID) Guidelines: Relevant for immunodeficiency aspects.
• Studies:
  • Savitsky, K. et al. (1995). A single gene controlling ataxia-telangiectasia and ATM. Science, 268(5218), 1749-1753. (Landmark paper identifying the ATM gene.)
  • Taylor, A. M. R. et al. (2018). Ataxia-Telangiectasia: The ATM Gene and the Clinical Manifestations of the Disorder. Journal of Clinical Immunology, 38(2), 241-255. (Comprehensive review of the gene and clinical features).
  • Rothblum-Oviatt, C. et al. (2016). Ataxia-Telangiectasia: A Review. Orphanet Journal of Rare Diseases, 11(1), 179. (Detailed clinical and management review).
• Reviews:
  • Lavin, M. F., & Chessa, L. (2014). Ataxia-telangiectasia: an update on the pathogenesis and clinical management. Molecular Syndromology, 5(1), 22-30.
  • Perlman, S. et al. (2019). Ataxia-telangiectasia: A comprehensive review. Pediatric Neurology, 95, 3-13.
  • UpToDate and GeneReviews (NIH): Continuously updated resources provide evidence-based summaries for clinicians.